Sanofi to acquire Bioverativ in multi-billion dollar deal

Amy Schofield 23 January 2018

Sanofi is to acquire Bioverativ Inc.

The companies have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis). 

The transaction was unanimously approved by both the Sanofi and Bioverativ Boards of Directors.

Bioverativ is a biopharmaceutical company focused on therapies for haemophilia and other rare blood disorders.

Olivier Brandicourt, Sanofi's Chief Executive Officer, said: "Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ's success in driving new standards of care with its extended half-life factor replacement therapies."

Bioverativ Chief Executive Officer, John Cox, said: "Bioverativ was created to bring meaningful progress to people living with haemophilia and other rare blood disorders, and I am extremely proud of the accomplishments we've made toward that mission over the past year.

"Our Chairman, Brian Posner, our entire Board and I strongly believed our spin-off would create meaningful value for shareholders, and this transaction delivers tremendous value for the shareholders who have invested in and supported our mission."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.